Carisma Therapeutics (NASDAQ:CARM) Given Neutral Rating at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Carisma Therapeutics (NASDAQ:CARMFree Report) in a report issued on Monday,Benzinga reports.

CARM has been the subject of a number of other research reports. EF Hutton Acquisition Co. I raised shares of Carisma Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 30th. Baird R W downgraded Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 12th. D. Boral Capital lowered their price objective on Carisma Therapeutics from $24.00 to $12.00 and set a “buy” rating for the company in a research note on Monday, December 9th. Robert W. Baird cut Carisma Therapeutics from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $10.00 to $1.00 in a research note on Thursday, December 12th. Finally, BTIG Research lowered Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 10th. Five analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $4.94.

Read Our Latest Stock Report on CARM

Carisma Therapeutics Stock Performance

Shares of CARM opened at $0.43 on Monday. The company has a 50-day simple moving average of $0.89 and a two-hundred day simple moving average of $1.03. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.23 and a quick ratio of 3.23. The firm has a market capitalization of $17.96 million, a PE ratio of -0.28 and a beta of 1.44. Carisma Therapeutics has a one year low of $0.40 and a one year high of $3.16.

Carisma Therapeutics (NASDAQ:CARMGet Free Report) last released its earnings results on Thursday, November 7th. The company reported ($0.31) EPS for the quarter, meeting analysts’ consensus estimates of ($0.31). The company had revenue of $3.39 million during the quarter. Carisma Therapeutics had a negative return on equity of 957.20% and a negative net margin of 314.78%. On average, analysts anticipate that Carisma Therapeutics will post -1.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in Carisma Therapeutics by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 1,579,961 shares of the company’s stock valued at $3,587,000 after buying an additional 11,200 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Carisma Therapeutics in the second quarter worth $40,000. Wexford Capital LP grew its holdings in shares of Carisma Therapeutics by 75.5% in the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after acquiring an additional 15,000 shares during the period. Finally, Barclays PLC lifted its holdings in Carisma Therapeutics by 3,661,933.3% in the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after acquiring an additional 549,290 shares during the period. 44.27% of the stock is owned by hedge funds and other institutional investors.

About Carisma Therapeutics

(Get Free Report)

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.

See Also

Analyst Recommendations for Carisma Therapeutics (NASDAQ:CARM)

Receive News & Ratings for Carisma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carisma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.